| Literature DB >> 32610121 |
Chang Yeop Han1, Inkyung Kang2, Ingrid A Harten2, John A Gebe2, Christina K Chan2, Mohamed Omer1, Kimberly M Alonge1, Laura J den Hartigh1, Diego Gomes Kjerulf1, Leela Goodspeed1, Savitha Subramanian1, Shari Wang1, Francis Kim3, David E Birk4, Thomas N Wight2, Alan Chait5.
Abstract
Obesity is characterized by adipose tissue inflammation. Because proteoglycans regulate inflammation, here we investigate their role in adipose tissue inflammation in obesity. We find that adipose tissue versican and biglycan increase in obesity. Versican is produced mainly by adipocytes and biglycan by adipose tissue macrophages. Both proteoglycans are also present in adipose tissue from obese human subjects undergoing gastric bypass surgery. Deletion of adipocyte-specific versican or macrophage-specific biglycan in mice reduces macrophage accumulation and chemokine and cytokine expression, although only adipocyte-specific versican deletion leads to sustained improvement in glucose tolerance. Macrophage-derived biglycan activates inflammatory genes in adipocytes. Versican expression increases in cultured adipocytes exposed to excess glucose, and adipocyte-conditioned medium stimulates inflammation in resident peritoneal macrophages, in part because of a versican breakdown product, versikine. These findings provide insights into the role of adipocyte- and macrophage-derived proteoglycans in adipose tissue inflammation in obesity.Entities:
Keywords: adipose tissue inflammation; biglycan; insulin resistance; obesity; proteoglycans; versican
Mesh:
Substances:
Year: 2020 PMID: 32610121 PMCID: PMC7384517 DOI: 10.1016/j.celrep.2020.107818
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423